AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims

1. (currently amended) A method of treating or preventing or inhibiting solid tumor growth a neoplasia disease sensitive to the combination in a mammal, the method comprising administering to a mammal in need thereof of treatment for a neoplasia disease a therapeutically effective amount of a compound of the formula:

$$\begin{array}{c|c} & & & \\ & & &$$

wherein X and Y are the same or different halo group; R is H or lower alkyl; and pharmaceutically acceptable salts thereof; together with a chemotherapeutic agent selected from the group consisting of cyclophosphamide, methodtrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine.

2. (cancelled)

3. (previously presented) A method according to claim 1 wherein the compound is selected from the group consisting of:

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$$

4. (cancelled)

5. (currently amended) A method of treating or preventing or inhibiting solid tumor growth a neoplasia disease sensitive to the combination in a mammal, the method comprising administering to a mammal in need thereof of treatment for a neoplasia disease a therapeutically effective amount of a compound of the formula:

wherein X and Y are the same or different halo group; R is H or lower alkyl; or a pharmaceutically acceptable salt thereof; together with a chemotherapeutic agent selected from the group consisting of cyclophosphamide, methodtrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine.

6. (cancelled)

7. (previously presented) A method according to claim 5 wherein the compound is selected from the group consisting of:

HO
$$\stackrel{H}{\longrightarrow}$$
 $\stackrel{CO_2R}{\longrightarrow}$ \stackrel

8. (cancelled).

9. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound corresponding to claim 1 of the formula:

$$\begin{array}{c|c} & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

wherein X and Y are the same or different halo group; R is H or lower alkyl; or a pharmaceutically acceptable salt thereof, a chemotherapeutic agent selected from the group consisting of cyclophosphamide, methodtrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine; and a pharmaceutically acceptable carrier.

Claims 10-13 (cancelled).

14. (new) A pharmaceutical composition as set forth in claim 9, wherein the composition comprises a therapeutically effective amount of a compound selected from the group consisting of:

$$\begin{array}{c|c} & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

$$\begin{array}{c|c} & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

$$\begin{array}{c|c} & & & \\ & & \\ & & & \\ & & \\ & & \\ & & & \\ & & \\ & & & \\ & & \\ & & \\ & & & \\ & & \\ & & & \\ & &$$

$$\begin{array}{c} CO_2R \\ CO_2R \\$$

ÓН